Leukemia, Myeloid, Acute × Cytogenetic Analysis × Clear all Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Phase 1/2 Withdrawn
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia
Unknown
80 enrolled
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
14 enrolled 22 charts
SAMBA
Phase 2 Terminated
25 enrolled
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 2 Completed
26 enrolled 7 charts
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Phase NA Completed
52 enrolled 7 charts
Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers
Completed
35 enrolled
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Phase 1/2 Completed
37 enrolled
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Terminated
21 enrolled 8 charts
Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia
Completed
20 enrolled
S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Completed
3,341 enrolled
Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
Phase 3 Completed
25 enrolled 13 charts
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase 2/3 Completed
2,000 enrolled
Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
Unknown
200 enrolled